Aim Immunotech Inc (AIM) Stock Price, Quote & News

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 352 448 7797

Fax: 352 480 4620

Website: aimimmuno.com

Address:

2117 SW Highway 484, Ocala, United States

Zefram Jul. 13 at 8:46 PM

$AIM did you have sexual relations with an animal? that might explain it.

0 · Reply

ultimatebastos Jul. 13 at 7:42 PM

$AIM Something is on!

1 · Reply

ultimatebastos Jul. 12 at 11:57 AM

$AIM if the frauds would not be in trouble they would not be bashing 24/7. I want to see them bleed.

1 · Reply

rayk1 Jul. 11 at 8:31 PM

$AIM $INKT +700% maybe someone can show our CEO Equels how he can start fireworks with the right PR. But well,i forgot,he is too busy with his horses and book presentations

1 · Reply

jonjonson1234 Jul. 11 at 8:23 PM

$AIM From the most recent 10-Q, in the company's own words: "Our principal source of liquidity is our cash and cash equivalents, marketable securities, and proceeds from financing activities to provide the necessary funding to meet our obligations as they become due. We have suffered losses from operations and net cash used on operating activities for the year ended December 31, 2024 and for the period ended March 31, 2025, and have a working capital deficit as of December 31, 2024 and as of March 31, 2025. Additionally, our stockholders’ equity was below the minimum requirements for continued listing on the New York Stock Exchange American (“NYSE American”). These conditions raise substantial doubt regarding our ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. "

4 · Reply

Aimforsuccess Jul. 11 at 5:28 PM

$AIM The 22nd may be more of Tommy’s hype. He has no credability in my opinion. All one has to do is follow his statements over the last three years.

1 · Reply

S_Templar Jul. 11 at 4:36 PM

$AIM folks, I wouldn't overthink any pre hours spike on low volume. I would hope all brokers only allow limit orders but you never know.

1 · Reply

Teleboy Jul. 11 at 4:35 PM

$AIM This popped up in my inbox. Looks like AIM is presenting on 22 July or shortly thereafter. https://virtualinvestorco.com/summer-spotlight/

1 · Reply

ultimatebastos Jul. 11 at 3:25 PM

$AIM the criminals on Yahoo post lies and when you rectify them they try hiding is with a new lie…

1 · Reply

sschmid1 Jul. 11 at 12:47 PM

$AIM — The Tape Still Speaks 1/ Premarket spike this morning — up to ~$14 — then instantly crushed back to the $8S. No volume, no news. Just… reaction. Fast. 2/ Feels like another test: Is someone still watching? Are the shorties still around? Answer: Yes. They reacted. Instantly. 3/ But interesting pattern here: We’ve had weeks of silence. No new attacks, no price breakdown — even though AIM has been dead quiet. That’s not normal. 4/ What if the short players know someone’s watching now? 👀 SEC? FINRA? They’ve gone quiet… until a spike forces their hand. 5/ So now, it’s not aggression — it’s preservation. They react just enough to stay in control. To avoid triggering more attention. ⚠️ The illusion is intact… but barely. 💡 Stay sharp. Watch the tape. (Not investment advice)

3 · Reply

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Jun 20, 2025, 4:15 PM EDT - 23 days ago

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

Jun 17, 2025, 8:55 AM EDT - 26 days ago

AIM ImmunoTech Resumes Trading on NYSE American

Jun 12, 2025, 8:30 AM EDT - 4 weeks ago

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Jun 12, 2025, 8:00 AM EDT - 4 weeks ago

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Jun 11, 2025, 4:15 PM EDT - 4 weeks ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

May 13, 2025, 9:54 AM EDT - 2 months ago

Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:45 AM EDT - 2 months ago

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

Apr 7, 2025, 1:26 PM EDT - 3 months ago

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Apr 4, 2025, 4:45 PM EDT - 3 months ago

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

Apr 4, 2025, 4:05 PM EDT - 3 months ago

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)

Apr 1, 2025, 9:19 AM EDT - 3 months ago

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

Mar 28, 2025, 11:39 AM EDT - 3 months ago

Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 8:45 AM EDT - 4 months ago

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 28, 2025, 8:45 AM EST - 4 months ago

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Feb 26, 2025, 1:20 PM EST - 4 months ago

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Feb 26, 2025, 8:30 AM EST - 4 months ago

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

Feb 25, 2025, 8:30 AM EST - 4 months ago

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Feb 11, 2025, 8:45 AM EST - 5 months ago

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

Feb 11, 2025, 8:30 AM EST - 5 months ago

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

Feb 7, 2025, 8:50 AM EST - 5 months ago

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks

Jan 23, 2025, 8:50 AM EST - 6 months ago

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

Jan 22, 2025, 8:30 AM EST - 6 months ago

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

Jan 15, 2025, 9:05 AM EST - 6 months ago

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

Dec 17, 2024, 4:45 PM EST - 7 months ago

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Dec 17, 2024, 3:10 PM EST - 7 months ago

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

Dec 16, 2024, 8:00 AM EST - 7 months ago

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

Dec 14, 2024, 4:54 PM EST - 7 months ago

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

Dec 12, 2024, 3:00 PM EST - 7 months ago

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

Dec 12, 2024, 9:00 AM EST - 7 months ago

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

Dec 12, 2024, 8:16 AM EST - 7 months ago

Kellner Group Announces Support from Another Former AIM Senior Executive

Dec 11, 2024, 7:30 AM EST - 7 months ago

AIM's Clinical Strategy Under Incumbent Board Has Totally Failed

Dec 10, 2024, 10:20 AM EST - 7 months ago

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.

Dec 10, 2024, 7:30 AM EST - 7 months ago

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

Dec 6, 2024, 9:15 AM EST - 7 months ago

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

Dec 6, 2024, 8:34 AM EST - 7 months ago

Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card

Dec 5, 2024, 9:00 AM EST - 7 months ago

ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.

Dec 2, 2024, 8:00 AM EST - 7 months ago

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees to the Board

Nov 27, 2024, 3:30 PM EST - 8 months ago

AIM ImmunoTech Refutes Activist Group's False and Misleading Claims

Nov 27, 2024, 8:00 AM EST - 8 months ago

AIM ImmunoTech Announces Cash Conservation Plan

Nov 25, 2024, 8:00 AM EST - 8 months ago

AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders

Nov 19, 2024, 8:00 AM EST - 8 months ago

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

Nov 15, 2024, 10:32 AM EST - 8 months ago

AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript

Nov 15, 2024, 7:29 AM EST - 8 months ago

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 1:04 PM EST - 8 months ago

Aimia Inc. (AIMFF) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 9:00 AM EST - 8 months ago

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

Nov 4, 2024, 8:00 AM EST - 8 months ago

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

Oct 3, 2024, 8:45 AM EDT - 10 months ago

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

Sep 27, 2024, 8:00 AM EDT - 10 months ago

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

Aug 20, 2024, 8:30 AM EDT - 11 months ago

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Zefram Jul. 13 at 8:46 PM

$AIM did you have sexual relations with an animal? that might explain it.

0 · Reply

ultimatebastos Jul. 13 at 7:42 PM

$AIM Something is on!

1 · Reply

ultimatebastos Jul. 12 at 11:57 AM

$AIM if the frauds would not be in trouble they would not be bashing 24/7. I want to see them bleed.

1 · Reply

rayk1 Jul. 11 at 8:31 PM

$AIM $INKT +700% maybe someone can show our CEO Equels how he can start fireworks with the right PR. But well,i forgot,he is too busy with his horses and book presentations

1 · Reply

jonjonson1234 Jul. 11 at 8:23 PM

4 · Reply

Aimforsuccess Jul. 11 at 5:28 PM

$AIM The 22nd may be more of Tommy’s hype. He has no credability in my opinion. All one has to do is follow his statements over the last three years.

1 · Reply

S_Templar Jul. 11 at 4:36 PM

$AIM folks, I wouldn't overthink any pre hours spike on low volume. I would hope all brokers only allow limit orders but you never know.

1 · Reply

Teleboy Jul. 11 at 4:35 PM

$AIM This popped up in my inbox. Looks like AIM is presenting on 22 July or shortly thereafter. https://virtualinvestorco.com/summer-spotlight/

1 · Reply

ultimatebastos Jul. 11 at 3:25 PM

$AIM the criminals on Yahoo post lies and when you rectify them they try hiding is with a new lie…

1 · Reply

sschmid1 Jul. 11 at 12:47 PM

3 · Reply

sschmid1 Jul. 11 at 12:39 PM

$AIM Small Pre-market fireworks in $AIM today. Jumped from 9s to almost 14 — then slammed straight back to 8s within minutes. All on low volume and no news. If the shorties are still around… they definitely reacted. Felt like another test — and they didn’t hesitate to smash it back down. Low volume, low visibility = perfect conditions for manipulation. 💭 Watch closely. The tape still tells a story. (Not investment advice)

1 · Reply

ultimatebastos Jul. 10 at 11:05 PM

$AIM it would be so fantastic to see a mega deal take place eliminating the need to issue more stock destroying the criminal counterfeiters.

1 · Reply

ultimatebastos Jul. 10 at 9:23 PM

$AIM it would be so much fun if the croocks come to late with their criminal funny stuf and get totally ruined

0 · Reply

ultimatebastos Jul. 10 at 8:52 PM

$AIM the criminals are preparing more short attacks I wouldn’t be surprised if Tom takes them by surprise

1 · Reply

WallStreetIsNotEasy Jul. 10 at 4:10 PM

$AIM There is zero interest in this company as Tom has run it into the ground. Sad but true. Volume is beyond pathetic. Why haven’t they done an offering at market yet?? Got a feeling they are working on a partnership or private placement. With Ted’s savvy business knowledge leading the way. Biotech is red hot with deals all over the place. I really have no idea or inside info and just my gut feeling 🤷🏻‍♂️

0 · Reply

jonjonson1234 Jul. 10 at 4:02 PM

$AIM Any guesses as to when the next reverse split will be? My guess would be 18-24 months or so.

1 · Reply

Teleboy Jul. 10 at 2:50 PM

$AIM 2/2 Struggling CAR-T therapy bought out by Concentra. https://www.biospace.com/business/concentra-snags-another-struggling-biotech-as-cargo-accepts-200m-buyout

1 · Reply

Teleboy Jul. 10 at 2:48 PM

$AIM Recent deals in related bio-pharma: 1/2 https://www.biospace.com/deals/abbvie-scoops-up-ichnos-glenmarks-lead-myeloma-antibody-for-nearly-2b

0 · Reply

lktrader Jul. 10 at 2:02 PM

$AIM Tom wtf are you doing? Absolutely zero updates… unacceptable.

2 · Reply

rayk1 Jul. 10 at 1:15 PM

$AIM funny read from yahoo board....ist MikeP still with us ,or ultimate sh*t the last one fighting hard for a multibillion $ buyout???;))))) "Tom 13 minutes ago Remember when mike/hebmaster/jonjonson exclaimed that "The buy signal is in! Strong buy to $1.35" a day or two before the first FDA rejection of Ampligen? Using those shares, the current share price would be .000017556818 per share. Or in today's shares, his price target would be $71,280.00 per share. I guess that he is just going to have start pumping a lot harder to get shares of AIM up to his target price. "

0 · Reply

ultimatebastos Jul. 9 at 6:56 PM

$AIM the should most crrtainly look in to Ampligen https://www.yahoo.com/news/eu-aims-stockpile-critical-medical-111141700.html

0 · Reply

yolotothemooon Jul. 9 at 2:55 PM

$AIM https://youtu.be/ddnLCr0HNf4?si=_fWjEQSgkqcuYeXK

0 · Reply

Market Cap	6.95M
Revenue (ttm)	170,000.00
Net Income (ttm)	-17.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,188.24%
Debt to Equity Ratio	0.00

Volume	13,600
Avg Vol	7,071
Day's Range	N/A - N/A
Shares Out	764,000.00
Stochastic %K	49%
Beta	0.98
Analysts	Sell
Price Target	$150.00